Age: 75.0
Sex: F
Vaccine: COVID19
Symptoms: C-reactive protein, DNA antibody, Electrophoresis protein, Investigation, Magnetic resonance imaging head
Clinical narrative: ear perichondritis/perichondritis of pinna/polychondritis; ear perichondritis/perichondritis of pinna/polychondritis; UTI; chronic APR elevations; This is a spontaneous report received from a Consumer or other non HCP.  A 77-year-old female patient received BNT162b2 (BNT162B2), on 02Jun2022 as dose 4 (booster), single (Lot number: FM0173) at the age of 75 years intramuscular, in arm for covid-19 immunisation. The patient's relevant medical history included: "Allergic" (unspecified if ongoing); "Arthritis" (unspecified if ongoing); "Chronic pain disorder" (unspecified if ongoing); "Colon polyp" (unspecified if ongoing); "Combined form of senile cataract of both eyes" (unspecified if ongoing); "Deep vein thrombosis" (unspecified if ongoing); "Dry eyes" (unspecified if ongoing); "Geographic tongue" (unspecified if ongoing); "GERD (gastroesophageal reflux disease)" (unspecified if ongoing); "Hyperlipidemia" (unspecified if ongoing); "Laryngopharyngeal reflux (LPR)" (unspecified if ongoing); "Osteopenia" (unspecified if ongoing); "Preoperative clearance" (unspecified if ongoing); "Primary angle closure suspect", start date: 08Feb2021 (unspecified if ongoing), notes: bilateral; "Primary osteoarthritis of both first carpometacarpal joints" (unspecified if ongoing); "right thumb tendon transfer" (unspecified if ongoing); "hot flashes" (unspecified if ongoing); "night sweats" (unspecified if ongoing); "tibial plateau stress fracture", start date: 2019 (unspecified if ongoing); "SI pain" (unspecified if ongoing), notes: Previous SI pain but resolved with PT/HEP; "problems with stomach" (unspecified if ongoing); "Heartburn" (unspecified if ongoing). The patient's concomitant medications were not reported. Past drug history included: Prolia; Miacalcin, notes: nose spray; Fosamax. Vaccination history included: BNT162b2 (Dose 1, SINGLE , Site and Route of injection: Arm , Route of administration: Intramuscular , Batch/Lot number: EL1283), administration date: 21Jan2021, when the patient was 74-year-old, for Covid-19 immunization; BNT162b2 (Dose 2, SINGLE , Site and Route of injection: Arm , Route of administration: Intramuscular , Batch/Lot number: EM9809), administration date: 11Feb2021, when the patient was 74-year-old, for Covid-19 immunization; BNT162b2 (Dose 3 (BOOSTER), SINGLE , Site and Route of injection: Arm, Route of administration: Intramuscular , Batch/Lot number: FF8839), administration date: 06Oct2021, when the patient was 75-year-old, for Covid-19 immunization, reaction(s): "Relapsing polychondritis", "perichondritis of pinna, right/polychondritis", "Chronic APR elevations", "UTI", "the autoimmune response", "nasal chondritis", "pulsatile tinnitus", "Osteoporosis", "Raynaud's", "Losing weight", "mild TTP at right ear"; hepatitis b, administration date: 02Apr1996, when the patient was 49-year-old, for Immunization; hepatitis b, administration date: 07May1996, when the patient was 49-year-old, for Immunization; hepatitis b, administration date: 12Nov1996, when the patient was 50-year-old, for immunization; pneumococcal conjugate, administration date: 04Dec2015, when the patient was 69-year-old, for Immunization; pneumococcal polysaccharide 23-valent (pneumovax23), administration date: 16Feb2012, when the patient was 65-year-old, for Immunization; td, unspecified (td vaccine), administration date: 01Apr2007, when the patient was 60-year-old, for Immunization; tdap, administration date: 20Mar2015, when the patient was 68-year-old, for Immunization; zostavax (live zoster vaccine), administration date: 14Sep2012, when the patient was 66-year-old, for Immunization; influenza, administration date: 21Oct1993, when the patient was 47-year-old, for Immunization; influenza, administration date: 04Nov1994, when the patient was 48-year-old, for Immunization; influenza, administration date: 31Oct1995, when the patient was 49-year-old, for Immunization; influenza, administration date: 10Nov1998, when the patient was 52-year-old, for Immunization; influenza, administration date: 19Oct1999, when the patient was 53-year-old, for Immunization; influenza, administration date: 03Nov2000, when the patient was 54-year-old, for Immunization; influenza, administration date: 17Nov2009, when the patient was 63--old, for Immunization; influenza, administration date: 19Sep2015, when the patient was 69-year-old, for Immunization; influenza, administration date: 15Oct2016, when the patient was 70-year-old, for Immunization; influenza, administration date: 30Nov2017, when the patient was 71-year-old, for Immunization; influenza, administration date: 20Oct2018, when the patient was 72-year-old, for Immunization; influenza, administration date: 08Oct2019, when the patient was 72-year-old, for Immunization; influenza, administration date: 11Oct2019, when the patient was 73-year-old, for Immunization; influenza, administration date: 20Sep2020, when the patient was 74-year-old, for Immunization; influenza, administration date: 14Sep2021, when the patient was 75-year-old, for Immunization; influenza, administration date: 17Sep2022, when the patient was 76-year-old, for Immunization; Flu (Anatomical Site of Injection: Arm), administration date: Sep2021, when the patient was 75 years old, for Immunization. The following information was reported: POLYCHONDRITIS (medically significant), PERICHONDRITIS (medically significant), outcome "unknown" and all described as "ear perichondritis/perichondritis of pinna/polychondritis"; URINARY TRACT INFECTION (non-serious), outcome "not recovered", described as "UTI"; AST TO PLATELET RATIO INDEX INCREASED (non-serious), outcome "unknown", described as "chronic APR elevations". The event "ear perichondritis/perichondritis of pinna/polychondritis" required physician office visit. The patient underwent the following laboratory tests and procedures: Antibody test: (unspecified date) Normal; Antineutrophil cytoplasmic antibody: (unspecified date) Normal; Antinuclear antibody: (unspecified date) Normal, notes: Normal; Antiphospholipid antibodies: (unspecified date) Normal; AST to platelet ratio index increased: (unspecified date) Modest chronic APR elevations, notes: Modest chronic APR elevations; C-reactive protein: (unspecified date) 20.7; DNA antibody: (unspecified date) Normal; Electrophoresis protein: (unspecified date) with possible monoclonal; Complements: (unspecified date) Normal; (unspecified date) Normal; (unspecified date) Normal, notes: Normal; (unspecified date) Normal; Magnetic resonance imaging head: (unspecified date) Normal; Red blood cell sedimentation rate increased: (Mar2023) 33. Therapeutic measures were taken as a result of polychondritis, perichondritis, urinary tract infection. Treatment included: Perichondritis of pinna, right; Polychondritis: ciprofloxacin (CIPRO) 750 mg tablet; Take 1 tablet (750 mg total) by mouth 2 (two) times a day for 7 days. Macrobid antibiotic for UTI.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202300300744 same patient/vaccine, different dose/events;US-PFIZER INC-PV202300173848 same patient/vaccine, different dose (dose 3)/events;US-PFIZER INC-202400032946 same patient/vaccine, different dose (dose 5)/events;